Annual
Report
2021
“
We would like to take this opportunity to thank you, dear shareholders, for your trust and unwavering support over the past years. Although recent global events have disrupted the environment in which we operate, rest assured that innovation and value creation remain at the centre of our focus. We look forward to achieving further major accomplishments in 2022.
Leon Van Rompay
Chief Executive Officer
2021 Highlights
R&D Pipeline
Estetrol in Women’s Health and Beyond
Contraception
First estetrol-based product launched
Menopause
Positive top-line results Phase III
Neuroprotection, Wound healing
Launch of Clinical Program on neuroprotection
Complex Therapeutics
Contraception
Launched in Europe, Canada & Chile
Menopause & Osteoporosis
Commercialized in about 40 countries
Breast & prostate cancer
Full global Licensing rights
Mithra CDMO
Brand new manufacturing facility fully dedicated to fill & finish production of complex liquid injectables and biologicals in vials, pre-filled syringes or cartridges
Partnership with the Belgian biotech ExeVir for the manufacturing of innovative Covid-19 treatments at Mithra CDMO’s new Injectable Facility
In 2021, 28% green energy produced by 5000 solar panels
252
collaborators
87
new hiring
56
Women
44
Men
Key Figures
Revenues
22.7
million
First product sales Estelle®
13.4
million
Still around
290
million cash
to be collected for Estelle® out-licensing
and sales related milestones
ESG Strategy
“